




RealRate

PHARMACEUTICAL 2022

Nektar Therapeutics
Rank 292 of 471

NEKTAR®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nektar Therapeutics compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Nektar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 27% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	795,581
Cost of Goods Sold	24,897
Intangible Assets	76,501
Liabilities, Current	85,200
Liabilities, Non-Current	129,328
Other Assets	184,597
Other Compr. Net Income	-1,862
Other Expenses	557
Other Liabilities	223,153
Other Net Income	-77,177
Other Revenues	101,907
Property and Equipment	60,510
Research and Development	400,269
Selling, General and Administrative Expense	122,844

Output Variable	Value in 1000 USD
Assets	1,117,189
Liabilities	437,681
Expenses	548,567
Revenues	101,907
Stockholders Equity	679,508
Net Income	-523,837
Comprehensive Net Income	-524,768
BaseVar	1,142,192
ECR before Limited Liability	123%
Economic Capital Ratio	248%